In another Phase I/IB study of BEZ235 in patients with advanced solid tumors including those with advanced breast cancer, the inhibition of PI3K/mTOR was not sufficient and adverse effects were prevalent [217]. This evidence concerns the gene MTOR and breast carcinoma.